Overcoming therapeutic resistance in oncology: The prospects of inorganic nanotheranostics.
2/5 보강
TL;DR
It is explored how translational frameworks, rational trial design, and platform-specific engineering are reshaping what is now clinically feasible in drug development, and what remains to be achieved to move beyond proof-of-concept into clinically meaningful benefits for patients with cancer.
OpenAlex 토픽 ·
Nanoplatforms for cancer theranostics
Nanoparticle-Based Drug Delivery
Cancer Research and Treatments
It is explored how translational frameworks, rational trial design, and platform-specific engineering are reshaping what is now clinically feasible in drug development, and what remains to be achieved
APA
Wenjia Zhang, J. ma, et al. (2026). Overcoming therapeutic resistance in oncology: The prospects of inorganic nanotheranostics.. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 86, 101361. https://doi.org/10.1016/j.drup.2026.101361
MLA
Wenjia Zhang, et al.. "Overcoming therapeutic resistance in oncology: The prospects of inorganic nanotheranostics.." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, vol. 86, 2026, pp. 101361.
PMID
41638182 ↗
Abstract 한글 요약
Cancer remains a leading cause of global mortality, with therapeutic resistance posing a formidable clinical obstacle. Inorganic nanotheranostics-multifunctional platforms integrating diagnostic and therapeutic capabilities-offer a promising strategy to overcome this barrier. This review systematically examines how distinct classes of inorganic nanomaterials (including iron, gadolinium, titanium, gold, manganese, carbon, and silicon-based systems) are engineered to counteract specific resistance mechanisms through unique physicochemical properties and biological interactions. We highlight their roles in enhancing drug delivery, modulating the tumor microenvironment, enabling precise imaging, and synergizing with various treatment modalities such as chemotherapy, radiotherapy, and immunotherapy. Advances in stimulus-responsive design, targeted delivery, and combinatorial therapies are discussed. Finally, we critically evaluate the translational challenges-including pharmacokinetics, long-term safety, and manufacturing scalability-and outline future directions toward clinically effective, personalized nanotheranostic interventions in oncology.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- USP32 Promotes Cancer Cell Invasion, Macrophage M2 Polarization, and CD8+ T Cell Apoptosis in Gastric Cancer Through Upregulation of DAPK1.
- Challenges to case-only analysis for interaction detection using polygenic risk scores: model assumptions and biases in large biobanks.
- United multi-omics and machine learning refine regulatory T cell-defined hepatocellular carcinoma subtypes.
- A SLC7A5-Specific Near-Infrared Fluorescent Probe for Cancer-Targeted Imaging Applications.
- Dynamic liver dysfunction predicts poor survival in patients with EGFR-mutant non-small cell lung cancer and liver metastases treated with EGFR tyrosine kinase inhibitors.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.